Table 4.
Engineered MSCs for treatment reaching the clinical stage
| Delivery system | Administration route | Sponsor | Indication | Development phase | Status | NCT number |
|---|---|---|---|---|---|---|
| MSCs secreting IFN-β | Intraperitoneal | M.D. Anderson Cancer Center, Dallas TX | Ovarian cancer | Phase 1 | Active, not recruiting | NCT02530047 |
| MV-NIS infected adipose tissue–derived MSCs | Intraperitoneal | Mayo Clinic, Rochester MN | Recurrent ovarian cancer | Phase 1/2 | Recruiting | NCT02068794 |
| Bone marrow-derived autologous MSCs infected with ICOVIR5, an oncolytic adenovirus (CELYVIR) | Intravenous | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | Metastatic and refractory solid tumors | Phase 1/2 | Completed | NCT01844661 |
| MSCs genetically modified to express TRAIL | Intravenous | University College, London | Lung adenocarcinoma | Phase 1/2 | Recruiting | NCT03298763 |
| Autologous human MSCs genetically modified to express HSV-TK | Intravenous | Apceth GmbH & Co. KG, Germany | Advanced gastrointestinal cancer | Phase 1/2 | Completed | 2012–003,741-15 (EudraCT number) |